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Primary care physicians believe they are delivering 
evidence-based care, understanding that adherence to 
evidence-based clinical guidelines results in tangible 
benefits in the populations for which they were devel-
oped. Unfortunately, most clinical guidelines are based 
on trial populations which are very different to primary 
care populations [1], and do not reflect the reality of 
multimorbidity in general practice [2–6]. Since patients 
with multimorbidity account for around eight in every 
10 primary care consultations [7], it is unsurpris-
ing that many primary care physicians find managing 
these patients challenging. Additionally, current clini-
cal guidelines do not provide guidance on how best to 
prioritize recommendations for individuals with multi-
morbidity, and may therefore result in over-treatment 
and polypharmacy, and a risk of overlooking patient 
preferences [2,8].
To illustrate the point, allow me to present Mary, an 
82-year-old, socially active woman living alone. Mary 
has been taking alendronate and calcium/vitamin C fol-
lowing a Colles fracture 5 years ago. She has difficulty 
walking as a result of osteoarthritis (for which she takes 
paracetamol and naproxen) and chronic obstructive 
pulmonary disease (for which she uses salbutamol for 
short-term symptom relief plus a salmeterol/fluticasone 
inhaler to prevent exacerbations). Mary is visiting her 
GP today to discuss her recently diagnosed stage 2 hyper-
tension (ambulatory blood pressure 162/92 mmHg), her 
fasting total:HDL (high-density lipoprotein cholesterol) 
of 5.3, and her newly diagnosed chronic kidney disease 
(CKD) stage 3aA2.
With strict adherence to all the current evidence-
based guidelines for her conditions, Mary would be 
leaving her appointment today with a prescription con-
taining all of the following:
 • Paracetamol 1 g four-times per day, as needed
 • Naproxen 250 mg twice-daily, as needed
 • Calcichew D3 Forte two tablets per day
 • Alendronate 70 mg once-weekly
 • Salbutamol and/or ipratropium bromide inhalers, as 
needed
 • Salmeterol/Fluticasone 50/500 mg inhaler, one puff 
twice-daily
 • Atorvastatin 20 mg, once daily
 • A calcium channel blocker, once daily
 • An angiotensin-converting enzyme (ACE) inhibitor, 
possibly at the maximum dose
 • Possibly a thiazide to achieve CKD blood pressure 
targets.
Patients like Mary are now the norm – not the excep-
tion – in primary care [5].
The Quality Outcomes Framework for general prac-
tice in the UK has resulted in more consistent use of 
evidence-based interventions, but has also led to far 
greater use of pharmacological therapies [9]. This has 
been compounded by a tendency towards over-diagno-
sis of premorbid disorders, with many patients receiving 
aggressive interventions for conditions that would 
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never have harmed them [10,11]. Polypharmacy is a 
risky business associated with causing or exacerbating 
other conditions, adverse drug reactions and interac-
tions, under-dosing of recommended drugs, medication 
errors, and poor adherence to treatment [12].
In Mary’s circumstances and for many other patients, 
we need to adopt a more rational, patient-centered 
approach to care, and consider deviating from the 
guidelines when it is safe and justifiable to do so. Most 
guidelines contain a statement encouraging clinicians 
to exercise “clinical judgement”; to do this we need to 
consider what the individual patient really wants, pri-
oritize those conditions most likely to do harm, and 
initiate only those treatments most likely to confer sub-
stantial benefits. We must make the best decisions we 
can in partnership with our patients.
Let us imagine that Mary expresses concern about 
the number of medications that she is being offered. She 
will do what her doctor advises, but would rather only 
take what is really necessary and wants to minimize her 
risk of side effects. Her treatment priorities are to reduce 
her risk of having a disabling stroke (a great fear) but 
she takes a philosophical approach about mortality and 
is not especially interested in taking drugs to increase 
longevity at her age; “You’ve got to die of something”. 
What her doctor needs to know now to help her make 
a treatment decision is: exactly how much good these 
treatments are likely to do her, how much harm they 
might cause, exactly how much risk reduction are they 
conferring, and a reduction in risk of what, exactly? An 
exploration of the evidence behind her guideline rec-
ommended treatment might lead her and her doctor to 
make some more prudent choices about her medication 
regime:
 • Treatment of stage 2 hypertension has been shown 
to reduce the risk of stroke from 5.2% to 3.3% over 
approximately 4 years [13], and a similar degree of 
benefit was observed in the Hypertension in the Very 
Elderly (HYVET) trial [14] with a target blood pres-
sure of <150/90 mmHg. A calcium channel blocker is 
the first class of drug recommended in current NICE 
hypertension guidance [15]. It would seem likely that 
Mary would opt for this treatment.
 • An ACE inhibitor is recommended in current NICE 
guidance for CKD in the presence of moderate 
albuminuria and hypertension. Examination of the 
evidence for this recommendation reveals that this 
intervention is based on trials of patients with diabe-
tes or severe, progressive CKD, and has been shown 
to reduce biochemical deterioration of CKD and the 
chance of end-stage CKD [16]. This is not a compa-
rable population, nor a treatment goal that is likely 
to be relevant for Mary. Treatment with an ACE 
inhibitor exposes her to risks of hyperkalemia, hypo-
tension, falls, and acute kidney injury.
 • Why should she remain on her Salmeterol/ Fluticasone 
inhaler? In chronic obstructive pulmonary disease 
with an FEV1 (forced expiratory volume in 1 s) 
<50% of predicted, this is recommended to reduce 
her risk of exacerbations and hospital admissions [17]. 
However, the absolute gain for this is very small. A 
Cochrane review [18] reported a 2.1% absolute risk 
reduction in the composite endpoint of exacerbations 
and hospital admissions, but also a 1.4% increase in 
absolute risk of pneumonia, conferring a ‘net benefit’ 
of merely 0.7% absolute risk reduction. Would Mary 
think this a worthwhile exercise?
 • Bisphosphonates have been shown to reduce the risk 
of osteoporotic fractures in a secondary prevention 
population [19], although the trial populations were 
younger than Mary and it is hard to extrapolate her 
likely gain from these drugs given the multifacto-
rial nature of fracture risk. However, they are likely 
to be a valuable intervention for her. Nevertheless, 
given that she has already been taking them for 
5 years, it may be reasonable to stop these treatments 
now as extension trials of bisphosphonates have not 
shown any longer term reduction in fracture risk 
[20]. Additionally, these drugs are associated with 
significant side effects, including gastrointestinal 
bleeding [21].
 • There is little evidence about the benefit for her in 
continuing oral calcium and vitamin D supplements 
without bisphosphonates. A trial in a comparable 
population showed no benefit [22].
 • The role of statins in the very elderly in a primary 
prevention context remains controversial. NICE 
guidance [23] recommends offering treatment but 
acknowledges the paucity of evidence in this age 
group. The PROSPER trial [24] in those aged over 
70 years showed no benefit for stroke reduction or 
total mortality (though some reduction in fatal and 
non-fatal myocardial infarction was observed) with 
pravastatin 40 mg versus placebo.
 • With regard to her analgesia, paracetamol and nap-
roxen are both recommended in current NICE 
guidance [25], but Mary and her doctor would wish 
to know the size of the potential risks of non-steroidal 
anti-inflammatory drugs, which include GI bleeds, 
acute kidney injury, and cardiovascular events.
Given all this extra information, it may well be that 
Mary and her doctor choose to rationalize her long-term 
medication so that she might remain on just paraceta-
mol, a calcium channel blocker and salbutamol inhaler 
as needed. In doing so, she may not lose much in terms 
of risk reduction, but gain a lot in reduced treatment 
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burden, risk of acute kidney injury, GI bleed, hypoten-
sion, falls, and possibly hospital admission.
But how might we achieve this sort of personalized 
assessment in everyday practice? Gathering this amount 
of information is prohibitively time consuming and 
requires high levels of confidence on the part of the doc-
tor interpreting it. Current clinical guidelines tend to be 
prescriptive and the evidence summaries behind them 
relatively inaccessible, do not consider the cumulative 
impact of treatment recommendations on people with 
multimorbidities, and do not state the potential risks and 
benefits of different treatments to the individual.
Primary care professionals are becoming increasingly 
frustrated by the prescriptive and additive nature of cur-
rent guidelines based on research that excluded most of 
the types of patients with multimorbidities we see every 
day [8,26–28]. Ideally, we would like to see clinical 
guidelines that are generalist-led, readily accessible and 
relevant to our work [2,4]. We need a clinically mean-
ingful evidence resource that draws on the excellent 
work presented in current guidelines, but would enable 
us to make prompt, patient-centred decisions based on 
an analysis of potential benefits and risk at the individ-
ual level. We would like to see data on absolute risk 
reductions with each intervention, numbers needed to 
treat in the context of a clear time frame, and numbers 
needed to harm clearly expressed, wherever possible. 
Breakdowns of composite endpoints would allow us to 
target treatment according to what the patient wants to 
achieve; for example, stroke versus non fatal myocardial 
infarction. We would like to have information about 
the applicability of study results to ‘real-world’ patients, 
with consideration given to the needs of different age 
groups, ethnicities, and patients with comorbidities/
multimorbidities [29].
Primary care physicians need rapid access to evi-
dence that matters – expressed in a way that is useful 
for patients – that can be found quickly during a con-
sultation. A framework for a web-based resource is 
being explored by the Royal College of General Prac-
titioners Standing Group on Overdiagnosis [30], and 
we hope to engage with others in the world of shared 
decision making to take this further. In the meantime, 
we should continue to be alert to the perils of poly-
pharmacy in our patients with multimorbidity, aim 
to balance the risk of under-treatment against that 
of over-treatment, and to maximize use of the most 
important interventions that offer the greatest benefit 
with the smallest harm [9].
We have a long way to go before we are adequately 
equipped to provide evidence-based, patient-centered 
care for our patients with multimorbidity, but at least 
the issues of over-diagnosis and over-treatment are now 
on the agenda, and there is a palpable hunger for change 






1 Steel N, Abdelhamid A, Stokes T, Edwards H, Fleetcroft R, Howe A, 
et al. A review of clinical practice guidelines found that they were 
often based on evidence of uncertain relevance to primary care 
patients. J Clin Epidemiol 2014;67:1251–7. View Item.
2 Hughes LD, McMurdo ME, Guthrie B. Guidelines for people 
not for diseases: the challenges of applying UK clinical guidelines 
to people with multimorbidity. Age Ageing 2013;42:62–9. View 
Item.
3 Greenhalgh T, Howick J, Maskrey N; Evidence Based Medicine 
Renaissance Group. Evidence based medicine: a movement in crisis? 
Br Med J 2014;348:g3725. View Item.
4 Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW. Adapt-
ing clinical guidelines to take account of multimorbidity. Br Med J 
2012;345:e6341. View Item.
5 Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. 
Epidemiology of multimorbidity and implications for health care, 
research, and medical education: a cross-sectional study. Lancet 
2012;380:37–43. View Item.
6 Smith SM, Soubhi H, Fortin M, Hudon C, O’Dowd T. Interven-
tions for improving outcomes in patients with multimorbidity in 
primary care and community settings. Cochrane Database Syst Rev 
2012;4:CD006560. View Item.
7 Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA. 
Epidemiology and impact of multimorbidity in primary care: a 
retrospective cohort study. Br J Gen Pract 2011;61:e12–21. View 
Item.
8 Heath I, Treadwell J. Bad guidelines and overtreatment in primary 
care. Report from the First Preventing Overdiagnosis Conference, 
Dartmouth, NH, USA, 2013 Sep 10–12. Available from: http://
www.preventingoverdiagnosis.net/documents/PODC2013.pdf 
[Last accessed Dec 10, 2014].
9 Duerden M, Avery T, Payne R. Polypharmacy and medicines opti-
misation: making it safe and sound. London: The King’s Fund, 2013. 
Available from: http://www.kingsfund.org.uk/sites/files/kf/field/
field_publication_file/polypharmacy-and-medicines-optimisation-
kingsfund-nov13.pdf [Last accessed Dec 11, 2014].
10 Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to 
stop harming the healthy. Br Med J 2012;344:e3502. View Item.
11 McCartney M. The patient paradox: why sexed-up medicine is bad 
for your health. London: Printer & Martin Ltd.; 2012. View Item.
14  J. Treadwell
© 2015 The Authors
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2015;5:11–14
12 Mannucci PM, Nobili A; REPOSI Investigators. Multimorbid-
ity and polypharmacy in the elderly: lessons from REPOSI. Intern 
Emerg Med 2014;9:723–34. View Item.
13 Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for 
mild hypertension. Cochrane Database Syst Rev 2012;8:CD006742. 
View Item.
14 Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, 
et al. Treatment of hypertension in patients 80 years of age or older. 
N Engl J Med 2008;358:1887–98. View Item.
15 National Institute for Health and Care Excellence. NICE clinical 
guideline 127. Hypertension: clinical management of primary hyper-
tension in adults. Manchester: NICE; 2011. Available from: http://
www.nice.org.uk/guidance/cg127 [Last accessed Jan 12, 2015].
16 National Institute for Health and Care Excellence. NICE clini-
cal guideline 182. Chronic kidney disease: early identification and 
management of chronic kidney disease in adults in primary and sec-
ondary care. Manchester: NICE; 2014. Available from: http://www.
nice.org.uk/guidance/cg182 [Last accessed Jan 12, 2015].
17 National Institute for Health and Care Excellence. NICE clinical 
guideline 101. Chronic obstructive pulmonary disease: management of 
chronic obstructive pulmonary disease in adults with primary and sec-
ondary care (partial update). Manchester: NICE; 2010. Available from: 
http://www.nice.org.uk/guidance/cg101 [Last accessed Jan 12, 2015].
18 Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R. Combined 
corticosteroid and long-acting-beta
2
-agonist in one inhaler versus 
placebo for chronic obstructive pulmonary disease. Cochrane Data-
base Syst Rev 2013;11:CD003794. View Item.
19 Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. 
Alendronate for the primary and secondary prevention of osteopo-
rotic fractures in postmenopausal women. Cochrane Database Syst 
Rev 2008;1:CD001155. View Item.
20 Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. 
Continuing bisphosphonate treatment for osteoporosis--for whom 
and for how long? N Engl J Med 2012;366:2051–3. View Item.
21 Peng YL, Hu HY, Luo LC, Hou MC, Lin HC, Lee FY. Aldendro-
nate, a bisphosphonate, increased upper and lower gastrointestinal 
bleeding risk: risk factor analysis from a nationwide population-
based study. Osteoporos Int 2014;25:1617–23. View Item.
22 Grant AM, Avenell A, Campbell MK, McDonald AM, MacLen-
nan GS, McPherson GC, et al. Oral vitamin D3 and calcium for 
secondary prevention of low-trauma fractures in elderly people 
(Randomized Evaluation of Calcium Or vitamin D, RECORD): a 
randomized placebo-controlled trial. Lancet 2005;365:1621–8. View 
Item.
23 National Institute for Health and Care Excellence. NICE clinical 
guideline 181. Lipid modification: cardiovascular risk assessment and 
the modification of blood lipids for the primary and secondary pre-
vention of cardiovascular disease. Manchester: NICE; 2014. Available 
from: http://www.nice.org.uk/guidance/cg181 [Last accessed Jan 
12, 2015].
24 Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, 
Cobbe SM, et al. Pravastatin in elderly individuals at risk of 
 vascular disease (PROSPER): a randomised controlled trial. Lancet 
2002;360:1623–30. View Item.
25 National Institute for Health and Care Excellence. NICE clini-
cal guideline 177. Osteoarthritis: care and management in adults. 
Manchester: NICE; 2014. Available from: http://www.nice.org.uk/
guidance/cg177 [Last accessed Jan 12, 2015].
26 Mercer SW, Guthrie B, Furler J, Watt GCM, Hart JT. Multimorbidity 
and the inverse care law in primary care. Br Med J 2012;344:e4152. 
View Item.
27 Smith SM, Bayliss EA, Mercer SW, Gunn J, Vestergaard M, Wyke S, 
et al. How to design and evaluate interventions to improve outcomes 
for patients with multimorbidity. J Comorbidity 2013;3:10–7. View 
Item.
28 Mercer SW, Gunn J, Bower P, Wyke S, Guthrie B. Managing patients 
with mental and physical multimorbidity. Br Med J 2012;345:e5559. 
View Item.
29 Salisbury CJ, Mercer SW, Fortin M. The ABC of Multimorbidity. 
Oxford: Wiley-Blackwell; 2014.
30 McCartney M, Treadwell J. The RCGP’s new standing group on 
overdiagnosis. Br Med J 2014;349:g4454. View Item.
